Real-World study tracks elidel use in asian kids with eczema
NCT ID NCT06052995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing how Elidel cream (pimecrolimus) is actually used in South and East Asian children aged 3 months to 12 years with mild to moderate atopic dermatitis (eczema). Researchers are tracking changes in eczema severity, itching, and sleep loss over the treatment period. The goal is to gather real-world data on how well the cream works in this specific population.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- pimecrolimus (Elidel cream)
- What this could lead to
- If successful, this study could provide real-world evidence on how well Elidel works for eczema in South and East Asian children, helping doctors tailor treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only looks at how the drug is already being used, not testing a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 130 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Approximately 130 patients will be enrolled.
- Ages
-
3 months to 12 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before patients are included in the study. Patients must meet all of the following inclusion criteria to be eligible for enrolment into the study: * Patients that have been prescribed Elidel® according to the local Package Insert prior to and independently from patient's enrolment into the study. * Patients of Asian ethnicity * Patients within following age group for respective countries as defined below: Malaysia: Patients \> 2 years and \<12 years old. Hong Kong: Patients \>3 months and \<12 years old. Thailand: Patients \>3 months and \<12 years old. Taiwan: Patients \>3 months and \<12 years old. * Signed informed consent from patient and (as per local regulations) if applicable from parent(s) or legal guardian(s) in compliance with local requirements * Patients with mild to moderate AD (SCORAD Index \<50) Exclusion Criteria: Patient candidates must not be enrolled in the study if they meet any of the following criteria: * Patients for whom Elidel® is not recommended accordingly to the local Package Insert * Patients with severe AD (SCORAD Index ≥50) * Receiving systemic glucocorticoids, antibiotics, antifungals, immunomodulators, antihistamines and ultraviolet radiation therapy within the last 4 weeks before inclusion * Receiving any topical AD-effective drugs within the last 2 weeks before inclusion * Pregnant and/or breastfeeding women * Patients or parent(s) / legal guardian (as applicable) that are not able to fulfil study requirements according to investigator's opinion * Patients or parent(s) / legal guardian (as applicable) that refuse to participate to the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mild to moderate atopic dermatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Viatris Clinical Site
Kuala Lumpur, Kuala Lumpur, 50300, Malaysia
-
Viatris Clinical Site
Ipoh, Perak, 31400, Malaysia
-
Viatris Clinical Site
Petaling Jaya, Selangor, 47810, Malaysia
-
Viatris Clinical Site
Kaohsiung City, Niaosong, 83301, Taiwan
-
Viatris Clinical Site
Taichung, Taiwan, 402306, Taiwan
-
Viatris Clinical Site
Taichung, Xitun, 40705, Taiwan
-
Viatris Clinical Site
Phu Wiang, Changwat Khon Kaen, 40002, Thailand
-
Viatris Clinical Site
Khlong Luang, Changwat Pathum Thani, 12120, Thailand
-
Viatris Clinical Site
Bangkok, 10330, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.